Hu Dan, Liu Qing, Lin Xiandong, Zhang Hejun, Lin Jinxiu, Zheng Xiongwei, Peng Feng
Department of Pathology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China.
Department of Cardiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
J Cancer. 2019 Jan 1;10(2):504-509. doi: 10.7150/jca.26583. eCollection 2019.
The receptor for advanced glycation end products (RAGE) is an oncogenic trans-membranous receptor expressed in many cells. The aim of this study was to clarify the association between gene 4 single nucleotide polymorphisms (SNPs) and the risk, invasion, metastasis and overall survival of gastric cancer. We performed a hospital-based case-control study involving 369 gastric cancer patients and 493 cancer free controls. Four widely-studied SNPs, rs1800625 (T-429C), rs1800624 (T-374A), rs2070600 (Gly82Ser) and rs184003 (G1704T) in RAGE gene, were genotyped by the polymerase chain reaction - ligase detection reaction method. The gene rs1800625 TT genotype and T allele were significantly associated with a reduced risk of gastric cancer (TT vs. CC: adjusted odds ratio [OR]: 0.72, 95% CI: 0.55-0.95, =0.021; T vs. C: adjusted OR: 0.67, 95% CI: 0.46-0.97, =0.032). No hints of significance were detected for the other three SNPs in association with gastric cancer risk. Moreover, rs1800625 and rs184003 were significantly associated with tumor clinical stage (=0.010 and 0.032, respectively). Survival curves differed significantly between the genotypes of rs1800625. gene SNP rs1800625 was significantly associated with gastric cancer risk, and rs1800625 and rs184003 were related to tumor clinical stage, indicating that gene may be a gastric cancer-susceptibility gene.
晚期糖基化终末产物受体(RAGE)是一种在许多细胞中表达的致癌跨膜受体。本研究的目的是阐明基因4单核苷酸多态性(SNP)与胃癌风险、侵袭、转移及总生存期之间的关联。我们开展了一项基于医院的病例对照研究,纳入369例胃癌患者和493例无癌对照。采用聚合酶链反应-连接酶检测反应法对RAGE基因中4个广泛研究的SNP,即rs1800625(T-429C)、rs1800624(T-374A)、rs2070600(Gly82Ser)和rs184003(G1704T)进行基因分型。基因rs1800625的TT基因型和T等位基因与胃癌风险降低显著相关(TT与CC比较:校正比值比[OR]:0.72,95%可信区间[CI]:0.55-0.95,P=0.021;T与C比较:校正OR:0.67,95%CI:0.46-0.97,P=0.032)。未检测到其他三个SNP与胃癌风险相关的显著线索。此外,rs1800625和rs184003与肿瘤临床分期显著相关(分别为P=0.010和0.032)。rs1800625各基因型之间的生存曲线差异显著。基因SNP rs1800625与胃癌风险显著相关,rs1800625和rs184003与肿瘤临床分期相关,表明该基因可能是胃癌易感基因。